Delving into the Latest Updates on IBRX-042 with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Neoplasms

Active Indication

Inactive Indication-

Originator Organization

ImmunityBio, Inc.

Active Organization

ImmunityBio, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are:
* What is the maximum tolerated dose of IBRX-042?
* How well does the study drug treat cancer?
* What effects the study drug may have on the human body and cancer?
Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administered by injection every 3 weeks for a total of 3 injections.

Start Date14 Jun 2024

Sponsor / Collaborator

ImmunityBio, Inc.

100 Clinical Results associated with IBRX-042

Login to view more data

100 Translational Medicine associated with IBRX-042

Login to view more data

100 Patents (Medical) associated with IBRX-042

Login to view more data

100 Deals associated with IBRX-042

Login to view more data